A phase 0 clinical trial to evaluate the neuropharmacological profile of posaconazole for glioblastoma.

Neurooncol Adv · 2026 · PMC13394498 · PMID 42494994

Europe PMC DOI

hedged sentences

0.3500

closest p · 7.0× alpha

0.3500

boldest claim

The sentences

failed to reach statistical significanceP = .35not close (p > 0.1)

BCL2 expression was slightly lower in the PCZ-treated group compared to controls when combining the core and peripheral tumor samples, though this failed to reach statistical significance (536.3 vs 307.8 pg/ml, P = .35).

also in 6,035 other papers

a slight trendno p-value reported

There was a slight trend towards decreased lactate levels in PCZ-treated samples compared to control in the combined group (154.5 vs 46.7 mlU/ml), but this failed to reach significance in the core (115.0 vs 62.6 mlU/ml, P > .99) and the periphery (194 vs 111.17 mlU/ml, P = .80).

also in 4,078 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.